Bernhard Wörmann

12.6k total citations · 2 hit papers
173 papers, 6.3k citations indexed

About

Bernhard Wörmann is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Bernhard Wörmann has authored 173 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Hematology, 44 papers in Oncology and 41 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Bernhard Wörmann's work include Acute Myeloid Leukemia Research (79 papers), Acute Lymphoblastic Leukemia research (29 papers) and Hematopoietic Stem Cell Transplantation (23 papers). Bernhard Wörmann is often cited by papers focused on Acute Myeloid Leukemia Research (79 papers), Acute Lymphoblastic Leukemia research (29 papers) and Hematopoietic Stem Cell Transplantation (23 papers). Bernhard Wörmann collaborates with scholars based in Germany, United States and Austria. Bernhard Wörmann's co-authors include Wolfgang Hiddemann, Thomas Büchner, Achim Heinecke, Claudia Schoch, Michael Unterhalt, Eva Hoster, Christa Fonatsch, Martin Dreyling, Wolfgang E. Berdel and Bernd Metzner and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Bernhard Wörmann

163 papers receiving 6.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Eva Hoster, Hermann Einsele et al. profile →
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

2022 110 citations Annika Fendler, Elisabeth G.E. de Vries et al. Nature Reviews Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bernhard Wörmann	3.3k	1.9k	1.9k	1.6k	1.5k	173	6.3k
Joseph O. Moore	3.3k 1.0×	1.9k 1.0×	1.8k 0.9×	997 0.6×	1.5k 1.0×	148	6.6k
Rena Buckstein	2.5k 0.7×	1.5k 0.8×	1.6k 0.8×	1.4k 0.9×	1.6k 1.0×	191	5.1k
Peter A. Cassileth	4.0k 1.2×	2.3k 1.2×	1.9k 1.0×	2.1k 1.3×	2.2k 1.4×	127	8.0k
Norbert Claude Gorin	4.4k 1.3×	1.9k 1.0×	926 0.5×	991 0.6×	1.5k 1.0×	188	6.9k
Anthony S. Stein	3.9k 1.2×	2.9k 1.5×	1.5k 0.8×	873 0.5×	934 0.6×	242	6.8k
Anjali S. Advani	3.5k 1.1×	2.9k 1.5×	1.6k 0.8×	1.2k 0.7×	1.2k 0.8×	298	7.1k
F Bauters	5.2k 1.6×	1.4k 0.7×	2.6k 1.3×	941 0.6×	3.0k 2.0×	211	7.3k
Martin F. Fey	2.1k 0.6×	3.0k 1.5×	3.1k 1.6×	1.2k 0.7×	927 0.6×	189	8.0k
Gary Spitzer	3.3k 1.0×	3.0k 1.5×	1.3k 0.7×	1.6k 1.0×	1.3k 0.9×	219	7.3k
Gérald Marit	5.9k 1.8×	3.3k 1.7×	3.3k 1.7×	1.8k 1.1×	2.2k 1.4×	193	8.6k

Countries citing papers authored by Bernhard Wörmann

Since Specialization

Citations

This map shows the geographic impact of Bernhard Wörmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard Wörmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard Wörmann more than expected).

Fields of papers citing papers by Bernhard Wörmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard Wörmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard Wörmann. The network helps show where Bernhard Wörmann may publish in the future.

Co-authorship network of co-authors of Bernhard Wörmann

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhard Wörmann. A scholar is included among the top collaborators of Bernhard Wörmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhard Wörmann. Bernhard Wörmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mölken, Maureen Rutten‐van, Bernhard Wörmann, Daniel Widmer, et al.. (2025). Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy. Journal of Market Access & Health Policy. 13(1). 6–6.

Solà-Morales, Oriol, C Martin Saborido, Wim Goettsch, et al.. (2024). The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy. SHILAP Revista de lepidopterología. 12(3). 128–143. 3 indexed citations

Matzdorff, Axel, Sonja Alesci, Johanna Gebhart, et al.. (2023). Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland. Oncology Research and Treatment. 46(Suppl. 2). 5–44. 13 indexed citations

Schildmann, Jan, Christian Junghanß, Michael Oldenburg, et al.. (2023). Ärztlich assistierte Selbsttötung. GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen). 30(1). 31–37. 1 indexed citations

Matzdorff, Axel, Sonja Alesci, Johanna Gebhart, et al.. (2022). Expertenreport Immunthrombozytopenie – Aktuelle Diagnostik und Therapie. Oncology Research and Treatment. 46(Suppl. 1). 7–56.

Fendler, Annika, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.. (2022). COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology. 19(6). 385–401. 110 indexed citations breakdown →

Wörmann, Bernhard, et al.. (2021). Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?. Oncology Research and Treatment. 44(Suppl. 1). 2–26. 1 indexed citations

Hornung, Roman, Vindi Jurinović, Aarif M.N. Batcha, et al.. (2018). Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia. Scientific Reports. 8(1). 11293–11293. 10 indexed citations

Kliesch, Sabine, et al.. (2012). Klinefelter-Syndrom und Krebs. Journal für Kardiologie (Krause & Pachernegg GmbH). 21(4). 11–15. 1 indexed citations

10.

Dufour, Annika, Friederike Schneider, Klaus H. Metzeler, et al.. (2009). Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome. Journal of Clinical Oncology. 28(4). 570–577. 189 indexed citations

11.

Büchner, Thomas, Wolfgang E. Berdel, Claudia Haferlach, et al.. (2008). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology. 27(1). 61–69. 232 indexed citations

12.

Griesinger, Frank, Michael Falk, Anja Renziehausen, et al.. (1999). Leukaemia‐associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. British Journal of Haematology. 105(1). 241–255. 49 indexed citations

13.

Griesinger, Frank, Michael Falk, Anja Renziehausen, et al.. (1999). Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. British Journal of Haematology. 105(1). 241–255.

14.

Kern, Wolfgang, Gerhard Behre, Andrea Kerkhoff, et al.. (1998). Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia. Cancer. 83(2). 291–301. 13 indexed citations

15.

Kern, Wolfgang, Jan Braess, Roland J. Fuchs, et al.. (1998). Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. Leukemia. 12(10). 1522–1526. 7 indexed citations

16.

Kern, Wolfgang, Carlo Aul, Georg Maschmeyer, et al.. (1998). Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. Annals of Hematology. 77(3). 115–122. 18 indexed citations

17.

Kern, Wolfgang, Eberhard Schleyer, Michael Unterhalt, et al.. (1997). High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Cancer. 79(1). 59–68. 1 indexed citations

18.

Wörmann, Bernhard, Christoph Reuter, M. Zühlsdorf, Th. Büchner, & W. Hiddemann. (1994). Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.. PubMed. 21(6 Suppl 16). 39–43. 4 indexed citations

19.

Büchner, Th., Wolfgang Hiddemann, Bernhard Wörmann, et al.. (1985). Differential pattern of DNA-Aneuploidy in human malignancies. Pathology - Research and Practice. 179(3). 310–317. 113 indexed citations

20.

Mellin, W., et al.. (1985). Biological Characterization of Human Bone Tumors. Pathology - Research and Practice. 180(6). 619–625. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact